Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid

Sanofi-Aventis recently presented promising data on Dupixent, an investigative treatment for bullous pemphigoid (BP), at the 2025 American Academy of Dermatology Annual Meeting. The pivotal ADEPT study results showed significant benefits, with 20% of Dupixent recipients achieving sustained disease remission at 36 weeks, compared to 4% for the placebo group. Dupixent also reduced disease severity, itching, and reliance on oral corticosteroids and rescue medication.

BP is a chronic skin disease marked by severe itching and blistering, predominantly affecting the elderly. Existing treatments pose challenges due to their immunosuppressive nature. Dupixent, targeting type 2 inflammation, demonstrated a notable reduction in symptoms, providing a potential new therapeutic option. Regulatory submissions are underway in the US and EU to establish Dupixent as the first targeted medication for BP.

While safety and efficacy are still under investigation, Dupixent's data is under review by regulatory authorities. The FDA has acknowledged Dupixent's potential by granting it orphan drug designation, with a decision expected by June 20, 2025.